{"id":2918,"date":"2020-06-04T07:46:03","date_gmt":"2020-06-04T07:46:03","guid":{"rendered":"http:\/\/novalab.bold-themes.com\/demo-02\/?page_id=2918"},"modified":"2026-02-09T13:21:01","modified_gmt":"2026-02-09T12:21:01","slug":"partner","status":"publish","type":"page","link":"https:\/\/impact-acmproject.eu\/lv\/partner\/","title":{"rendered":"Partneris"},"content":{"rendered":"

<\/div><\/div>
<\/div>

PARTNER<\/span><\/span><\/h1>
Projekta partneris<\/div><\/header>
<\/div><\/div><\/div><\/div>
<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>
\"bt_bb_section_bottom_section_coverage_image\"<\/div><\/section>
\"https:\/\/impact-acmproject.eu\/wp-content\/uploads\/2023\/11\/universita_padova.webp\"<\/span><\/div>
<\/div><\/div><\/div><\/div>

Universit\u00e0 degli Studi di Padova<\/span><\/span><\/h3><\/header>
<\/div>
<\/div>
<\/p>\n

Padujas Universit\u0101tes Biolo\u0123ijas departaments tika izveidots 1983. gada oktobr\u012b, apvienojot dz\u012bvnieku biolo\u0123ijas, bot\u0101nikas un antropolo\u0123ijas instit\u016btus, k\u0101 ar\u012b Padujas Bot\u0101nisko d\u0101rzu un Kiod\u017eas j\u016bras biolo\u0123ijas staciju (Ven\u0113cija).<\/p>\n

K\u0101 projekta koordinators UNIDP nodro\u0161ina projekta m\u0113r\u0137u atbilst\u012bbu dot\u0101cijas un konsorcija nol\u012bguma (KN) noteikumiem. T\u0101s uzdevums ir uzlabot ACM pacientu stratifik\u0101ciju, noteikt nezin\u0101mas noz\u012bmes variantu ieguld\u012bjumu un izstr\u0101d\u0101t un raksturot attiec\u012bgos prekl\u012bniskos mode\u013cus. Turkl\u0101t t\u0101 ir atbild\u012bga par iesp\u0113jamo \u0113tikas jaut\u0101jumu identific\u0113\u0161anu un atrisin\u0101\u0161anu. UNIPD ar\u012b cie\u0161i sadarbojas ar partneriem, lai nov\u0113rt\u0113tu paredzam\u0101s \u0113tisk\u0101s probl\u0113mas un piev\u0113rstos t\u0101m, kas rodas projekta gait\u0101.<\/p>\n

\n<\/div>

<\/div>
t\u012bmek\u013ca vietne<\/span><\/a><\/div>
<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>
<\/div><\/div><\/div><\/div><\/div><\/div>

Consorzio Italbiotec<\/span><\/span><\/h3><\/header>
<\/div>
<\/div>
<\/p>\n

It\u0101lijas vado\u0161\u0101 bezpe\u013c\u0146as organiz\u0101cija biotehnolo\u0123ijas nozar\u0113. T\u0101 vada zin\u0101tnes att\u012bst\u012bbu un pozit\u012bvu zin\u0101\u0161anu nodo\u0161anu starp p\u0113tniec\u012bbas kopienu un r\u016bpniec\u012bbu, veidojot progres\u012bvu inov\u0101cijas ekosist\u0113mu, ko virza biotehnolo\u0123ijas jaunuz\u0146\u0113mumi, uz\u0146\u0113mumi, universit\u0101tes, kur sadarb\u012bba un zin\u0101\u0161anu apmai\u0146a veicina izaugsmi un ilgtsp\u0113j\u012bgu inov\u0101ciju. Consorzio Italbiotec, pateicoties sav\u0101m speci\u0101laj\u0101m zin\u0101\u0161an\u0101m, b\u016bs atbild\u012bgs par izplat\u012b\u0161anas, komunik\u0101cijas, apm\u0101c\u012bbas un izmanto\u0161anas pas\u0101kumiem ar augsta l\u012bme\u0146a m\u0113r\u0137i projekt\u0101 veidot un uztur\u0113t stabilu un efekt\u012bvu komunik\u0101cijas kult\u016bru. Strat\u0113\u0123ija ar\u012b veicin\u0101s to ieinteres\u0113to personu un daudzdal\u012bbnieku inform\u0113tu kopienu, kuri ir ieinteres\u0113ti un ap\u0146\u0113mu\u0161ies risin\u0101t IMPACT tematu, un veicin\u0101s t\u0101 inovat\u012bvo rezult\u0101tu optim\u0101lu izmanto\u0161anu.<\/p>\n

\n<\/div>

<\/div>
t\u012bmek\u013ca vietne<\/span><\/a><\/div>
<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>
<\/div>
\"https:\/\/impact-acmproject.eu\/wp-content\/uploads\/2023\/11\/italbiotec.webp\"<\/span><\/div><\/div><\/div><\/div><\/div><\/div>
<\/div><\/div><\/div><\/div><\/div><\/div>
\"https:\/\/impact-acmproject.eu\/wp-content\/uploads\/2023\/11\/maastricht.webp\"<\/span><\/div>
<\/div><\/div><\/div><\/div>

M\u0101strihtas Universit\u0101te<\/span><\/span><\/h3><\/header>
<\/div>
<\/div>
<\/p>\n

M\u0101strihtas Universit\u0101tes Sirds un asinsvadu slim\u012bbu skola (CARIM) ir pasaules m\u0113roga references centrs g\u0113nu regul\u0113\u0161anas meh\u0101nismu izp\u0113tei \u0123en\u0113tisko un ieg\u016bto sirds mazsp\u0113jas formu kontrol\u0113. In vivo un cilv\u0113ka in vitro mode\u013cus parasti izmanto, lai p\u0113t\u012btu cilv\u0113ka sirds slim\u012bbas, izmantojot molekul\u0101r\u0101s un \u0161\u016bnu biolo\u0123isk\u0101s pieejas, k\u0101 ar\u012b augstas caurlaidsp\u0113jas \u0123en\u0113tisk\u0101s skr\u012bninga iek\u0101rtas, transg\u0113na\/g\u0113na izsl\u0113g\u0161anas tehnolo\u0123iju, sirds fenotip\u0113\u0161anu un att\u0113lveido\u0161anas metodes. Kop\u0161 vair\u0101kiem gadiem, nodro\u0161inot piln\u012bgu un glob\u0101lu orientieri mikroRNS profil\u0113\u0161anai sirds mazsp\u0113jas gad\u012bjum\u0101, \u0161\u012b iest\u0101de tiek uzskat\u012bta par l\u012bderi sirds epi\u0123en\u0113tiskaj\u0101 jom\u0101 vis\u0101 pasaul\u0113.<\/p>\n

\n<\/div>

<\/div>
t\u012bmek\u013ca vietne<\/span><\/a><\/div>
<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>
<\/div><\/div><\/div><\/div><\/div><\/div>

AccelBio<\/span><\/span><\/h3><\/header>
<\/div>
<\/div>
<\/p>\n

AccelBio ir Portug\u0101les bezpe\u013c\u0146as p\u0113tniec\u012bbas un att\u012bst\u012bbas organiz\u0101cija, kas apvieno partnerus no farm\u0101cijas, biotehnolo\u0123ijas, akad\u0113miskaj\u0101m aprind\u0101m, riska kapit\u0101la un biotehnolo\u0123iju parka.<\/p>\n

AccelBio izmanto jaunas racion\u0101las pieejas, lai atbalst\u012btu z\u0101\u013cu atkl\u0101\u0161anas projektus prekl\u012bniskaj\u0101s f\u0101z\u0113s no akad\u0113miskaj\u0101m aprind\u0101m un jaunuz\u0146\u0113mumiem. Vi\u0146u kompetences jomas cita starp\u0101 ietver sirds un asinsvadu un neirolo\u0123isk\u0101s slim\u012bbas, imunolo\u0123iju, iekaisumu, infekciju, onkolo\u0123iju un nefrolo\u0123iju.<\/p>\n

Lai atbalst\u012btu z\u0101\u013cu izstr\u0101di, AccelBio saimniektehnolo\u0123iju platformas, tostarp progres\u012bvi organo\u012bdi, multiomika, skait\u013co\u0161anas biolo\u0123ija, bioinform\u0101tika un augstas caurlaidsp\u0113jas skr\u012bnings. Tulko\u0161anas komanda ir ar\u012b velt\u012bta tam, lai atbalst\u012btu p\u0113tniekus un uz\u0146\u0113m\u0113jus, izstr\u0101d\u0101jot ce\u013cvedi \u201cno so\u013ca l\u012bdz tirgum\u201d, iev\u0113rojot nozares paraugpraksi un novedot pie augstas kvalit\u0101tes z\u0101\u013cu kandid\u0101tiem.<\/p>\n

IMPACT ietvaros Accelbio izmantos savus unik\u0101li progres\u012bvos cilv\u0113ka sirds organo\u012bdus, lai veicin\u0101tu ACM pacientu stratifik\u0101ciju un atkl\u0101tu un apstiprin\u0101tu jaunus \u0161\u012bs slim\u012bbas darb\u012bbas meh\u0101nismus, biomar\u0137ierus un terapeitiskos m\u0113r\u0137us.<\/p>\n

\n<\/div>

<\/div>
t\u012bmek\u013ca vietne<\/span><\/a><\/div>
<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>
<\/div>
\"logo<\/span><\/div><\/div><\/div><\/div><\/div><\/div>
<\/div><\/div><\/div><\/div><\/div><\/div>
\"https:\/\/impact-acmproject.eu\/wp-content\/uploads\/2023\/11\/italfarmaco.webp\"<\/span><\/div>
<\/div><\/div><\/div><\/div>

Italfarmaco Spa (ITF)<\/span><\/span><\/h3><\/header>
<\/div>
<\/div>
<\/p>\n

Italfarmaco SpA ir priv\u0101ts daudznacion\u0101ls It\u0101lijas uz\u0146\u0113mums, kura galven\u0101 m\u012btne atrodas Mil\u0101n\u0101. T\u0101 darbojas It\u0101lij\u0101 un \u0101rvalst\u012bs farm\u0101cijas un \u0137\u012bmijas farm\u0101cijas nozar\u0113 ar t\u0101du uz\u0146\u0113mumu starpniec\u012bbu, kuros t\u0101 ir tie\u0161i vai netie\u0161i ieinteres\u0113ta. Italfarmaco tika dibin\u0101ta 1938. gad\u0101. Grupai ir modernas r\u016bpniecisk\u0101s iek\u0101rtas augstas kvalit\u0101tes farmaceitisko produktu ra\u017eo\u0161anai, un t\u0101 ir stingri ap\u0146\u0113musies veikt p\u0113t\u012bjumus, jo \u012bpa\u0161i sirds un asinsvadu, imunolo\u0123iskaj\u0101 un onkolo\u0123iskaj\u0101 jom\u0101.
\nIMPACT ietvaros ITF b\u016bs atbild\u012bgs par z\u0101\u013cu izstr\u0101di un z\u0101\u013cu skr\u012bninga testiem un str\u0101d\u0101s pie t\u0101, lai identific\u0113tu jaunus narkotik\u0101m l\u012bdz\u012bgus hemotipus ar v\u0113lamo profilu.<\/p>\n

\n<\/div>

<\/div>
t\u012bmek\u013ca vietne<\/span><\/a><\/div>
<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>
<\/div><\/div><\/div><\/div><\/div><\/div>

UMC Utrehta<\/span><\/span><\/h3><\/header>
<\/div>
<\/div>
<\/p>\n

Utrehtas Universit\u0101tes Medic\u012bnas centrs (UMC Utrecht) ir nacion\u0101li un starptautiski
\nAtz\u012bts ekspert\u012bzes centrs iedzimt\u0101m sirds slim\u012bb\u0101m. Taj\u0101 atrodas liela biobanka
\nkardiomiop\u0101tijas pacientu asinis un audi (biopsija, autopsija, transplant\u0101cija). UMC
\nUtrehta kalpo k\u0101 nacion\u0101lais nos\u016bt\u012b\u0161anas centrs pacientiem ar aritmiju
\nkardiomiop\u0101tija (ACM) un koordin\u0113 ACM pacientu valsts re\u0123istru (
\nN\u012bderlandes ACM re\u0123istrs), kur\u0101 pa\u0161laik ir vair\u0101k nek\u0101 2000 ACM pacientu un
\nradinieki.<\/p>\n

IMPACT ietvaros UMC Utrecht ievad\u012bs datus no pacientiem, kas iek\u013cauti ACM.
\nre\u0123istrs, kur\u0101 identific\u0113 pacientu kopas, kas izmanto m\u0101ksl\u012bgo intelektu. Identific\u0113tais
\nklasteri tiks valid\u0113ti starp modalit\u0101t\u0113m (EKG, sirds att\u0113lveido\u0161ana, bioparaugi). iek\u0161\u0101
\nturkl\u0101t UMC Utrecht veiks progres\u012bvus -omikas p\u0113t\u012bjumus ar ACM audu paraugiem,
\nieskaitot viena kodola transkriptomiku, in situ notver\u0161anu, RNS sekvenc\u0113\u0161anu un
\nproteomika. \u0160ie rezult\u0101ti p\u0113c tam tiks iek\u013cauti cit\u0101s darba pakotn\u0113s, lai noteiktu:
\niesp\u0113jamie narkotiku lieto\u0161anas m\u0113r\u0137i.<\/p>\n

\n<\/div>

<\/div>
t\u012bmek\u013ca vietne<\/span><\/a><\/div>
<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>
<\/div>
\"UMC<\/span><\/div><\/div><\/div><\/div><\/div><\/div>
<\/div><\/div><\/div><\/div><\/div><\/div>
\"Lutech\"<\/span><\/div>
<\/div><\/div><\/div><\/div>

Lutech Advanced Solutions SPA (LUTECH) - Kr\u0113slu, m\u0113be\u013cu, sporta pre\u010du veikals - Bru\u0146inieku 98,R\u012bga<\/span><\/span><\/h3><\/header>
<\/div>
<\/div>
<\/p>\n

Lutech Advanced Solutions izce\u013cas k\u0101 premier tehnolo\u0123iju risin\u0101jumu nodro\u0161in\u0101t\u0101js, kas ir slavens ar saviem inovat\u012bvajiem un progres\u012bvajiem IT pakalpojumiem. Ar \u012bpa\u0161u uzsvaru uz progres\u012bviem risin\u0101jumiem uz\u0146\u0113mums sniedz pla\u0161u pakalpojumu kl\u0101stu, s\u0101kot no digit\u0101l\u0101s p\u0101rveides un kiberdro\u0161\u012bbas l\u012bdz m\u0101ko\u0146dato\u0161anai un datu anal\u012bzei. Projekta IMPACT ietvaros Lutech ir ap\u0146\u0113mies uzlabot pirmskl\u012bnisko mode\u013cu fenotip\u0113\u0161anu un kl\u012bnisko lietder\u012bbu. M\u0113r\u0137is ir palielin\u0101t terapeitisko pieeju paredzam\u012bbu kl\u012bniskajos p\u0113t\u012bjumos un slim\u012bbu p\u0101rvald\u012bb\u0101. Turkl\u0101t Lutech ir akt\u012bvi iesaist\u012bts stabilu prekl\u012bnisko mode\u013cu izstr\u0101d\u0113 un raksturo\u0161an\u0101, veicinot p\u0113tniec\u012bbas metodolo\u0123iju un rezult\u0101tu visp\u0101r\u0113jo att\u012bst\u012bbu.<\/p>\n

\n<\/div>

<\/div>
t\u012bmek\u013ca vietne<\/span><\/a><\/div>
<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/section>
<\/div><\/div>
<\/div><\/div><\/div><\/section><\/p>","protected":false},"excerpt":{"rendered":"","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-2918","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/impact-acmproject.eu\/lv\/wp-json\/wp\/v2\/pages\/2918","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/impact-acmproject.eu\/lv\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/impact-acmproject.eu\/lv\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/impact-acmproject.eu\/lv\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/impact-acmproject.eu\/lv\/wp-json\/wp\/v2\/comments?post=2918"}],"version-history":[{"count":32,"href":"https:\/\/impact-acmproject.eu\/lv\/wp-json\/wp\/v2\/pages\/2918\/revisions"}],"predecessor-version":[{"id":4057,"href":"https:\/\/impact-acmproject.eu\/lv\/wp-json\/wp\/v2\/pages\/2918\/revisions\/4057"}],"wp:attachment":[{"href":"https:\/\/impact-acmproject.eu\/lv\/wp-json\/wp\/v2\/media?parent=2918"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}